Publications by authors named "A Spadano"
Article Synopsis
- - The study evaluates the effectiveness and safety of carfilzomib-based treatment regimens for young, fit patients with newly diagnosed multiple myeloma, comparing them to the current standard of care (bortezomib with high-dose melphalan and lenalidomide maintenance).
- - Conducted as a randomized, open-label trial across 42 centers in Italy, the study enrolled patients under 65, categorizing them into different treatment groups involving autologous stem-cell transplantation, carfilzomib, and lenalidomide.
- - Patients underwent four cycles of carfilzomib-based induction therapy, followed by stem-cell transplantation and then randomized to maintenance treatment either with carfilzomib plus
Background: In combination with dexamethasone, lenalidomide is prescribed in the oral treatment of Multiple Myeloma for patients who have received at least one previous therapy.
Objective: The objective of this study is to evaluate medication adherence to lenalidomide of Multiple Myeloma patients, as well as Progression Free Survival and Overall Survival one year from the beginning of the treatment.
Setting: The study was carried out in Pescara Hospital, in Italy.
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study.
Lancet Haematol
December 2020
Background: The phase 3 GIMEMA-MMY-3006 trial, which compared bortezomib, thalidomide, and dexamethasone (VTD) combination therapy with thalidomide and dexamethasone (TD) as induction therapy before and consolidation therapy after double autologous haematopoietic stem-cell transplantation (HSCT) for newly diagnosed multiple myeloma, showed the superiority of the triplet regimen over the doublet in terms of increased complete response rate and improved progression-free survival. We report the results from the final analysis of the study.
Methods: In this randomised, open-label, phase 3 study, patients aged 18-65 years with previously untreated symptomatic multiple myeloma and a Karnofsky Performance Status of 60% or higher were enrolled at 73 centres in Italy.
High-throughput DNA sequence analysis was used to screen for TET2 mutations in peripheral blood derived DNA from 97 patients with BCR-ABL-negative myeloproliferative neoplasms (MPNs). Overall six mutations in the coding region of the gene were identified in 7 patients with an overall mutational frequency of 7.2%.
View Article and Find Full Text PDF